Senti Current Deferred Revenue from 2010 to 2024

SNTI Stock  USD 2.12  0.06  2.75%   
Senti Biosciences' Current Deferred Revenue is decreasing with slightly volatile movements from year to year. Current Deferred Revenue is estimated to finish at about 1.1 M this year. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
989 K
Current Value
1.1 M
Quarterly Volatility
431.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Senti Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senti Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 4.7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 10.86, Dividend Yield of 0.0 or PTB Ratio of 0.42. Senti financial statements analysis is a perfect complement when working with Senti Biosciences Valuation or Volatility modules.
  
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.

Latest Senti Biosciences' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Senti Biosciences over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Senti Biosciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Senti Biosciences' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

Senti Current Deferred Revenue Regression Statistics

Arithmetic Mean1,767,360
Geometric Mean1,700,890
Coefficient Of Variation24.39
Mean Deviation338,272
Median1,998,000
Standard Deviation431,119
Sample Variance185.9B
Range1.2M
R-Value(0.73)
Mean Square Error92.6B
R-Squared0.54
Significance0
Slope(70,658)
Total Sum of Squares2.6T

Senti Current Deferred Revenue History

20241.1 M
2023989 K
2022799 K
20211.7 M

About Senti Biosciences Financial Statements

Investors use fundamental indicators, such as Senti Biosciences' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Senti Biosciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue989 K1.1 M

Currently Active Assets on Macroaxis

When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(15.59)
Revenue Per Share
0.075
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.33)
Return On Equity
(1.11)
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.